<DOC>
	<DOCNO>NCT01116791</DOCNO>
	<brief_summary>The majority patient upper gastrointestinal cancer , gastric , biliary , pancreatic carcinoma , present metastatic disease , extremely poor survival , irrespective type treatment modality . The aim current monocentric phase II study evaluate patient effectiveness cytoreductive surgery ( CRS ) plus hyperthermic intraoperative peritoneal chemotherapy cisplatin ( HIPC ) . The study design least 80 % power detect 40 % increase 1-year overall survival common stratum ( gastric-biliary-pancreas ) CRS+HIPC . Over anticipated period 2 year , 60 patient undergo CRS + HIPC . Translational research quantify perioperative circulate peritoneal tumour cell , base real-time RT-PCR CEA EpCAM . Plasma concentration cytokine determine IL-1β , IL-2 , IL-6 , IL-8 , IL-10 , IL-12p70 , IL-13 , IFN-γ , VEGF several time-points . Systemic immunological change assess flow cytometric quantification relative proportion absolute number B- T-lymphocytes , NK cell , effector T cell , HLA-DR+ T cell , regulatory T cell . Gene-expression study perform use Affymetrix HG U133 Plus 2.0 array primary metastatic tissue sample .</brief_summary>
	<brief_title>Cytoreductive Surgery ( CRS ) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy ( HIPC ) With Cisplatin Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer</brief_title>
	<detailed_description>ASSESSMENT TUMOUR BURDEN • Tumour burden assess use diagnostic imaging modality verify surgical laparoscopic evaluation CRS+HIPC - Primary tumour Biliary adenocarcinoma - Intrahepatic cholangiocellular carcinoma &lt; 3 cm diameter - Extrahepatic cholangiocellular carcinoma without invasion major blood vessel ( portal vein , hepatic artery , coeliac trunk ) Gastric adenocarcinoma Macroscopic surgical margin 5 cm need obtain complete tumour removal Pancreatic adenocarcinoma Tumours locate head , body tail pancreas without portal hypertension due complete encasement mesenteric/portal vein collateral venous circulation - Liver metastases - Only liver metastases stable disease clinical response prior systemic therapy period least 3 month eligible - Not 3 metastasis , measure 3 cm less diameter - Solitary liver metastasis small 5 cm diameter locate periphery ventral segment ( Sg 2-6 ) - Peritoneal metastases - Sugarbaker 's peritoneal cancer index ( PCI ) use assess peritoneal tumour burden 28 . The completeness cancer resection ( CCR ) assess surgeon end CRS ; CCR-0 macroscopic residual tumour , CCR-1 residual tumour nodule great 2.5 mm , CCR-2 residual tumour nodule large 2.5 mm diameter . - Patients PCI &lt; 20 eligible study 11 . THERAPEUTIC INTERVENTION - CRS define macroscopic tumour removal use surgical resection and/or LAT Primary tumour Biliary adenocarcinoma - Intrahepatic cholangiocellular carcinoma - Deep parenchymatous tumour treat LAT - Superficial peripheral tumour treat resection LAT - Distance tumour major biliary structure ( right , leave , main hepatic duct ) need &gt; 1 cm - Extrahepatic cholangiocellular tumour treat surgical resection biliodigestive reconstruction - Distal cholangiocellular tumour intrapancreatic location treat pancreaticoduodenectomy LAT 90°C - Lymph node around hepatoduodenal ligament remove Gastric adenocarcinoma - Partial gastrectomy perform either proximal distal gastrectomy dependent tumour location size - Total gastrectomy perform patient signet-ring cell cancer linitis plastica - Tumour-draining lymph node remove Pancreatic adenocarcinoma - Tumours locate head pancreas radiologic macroscopic vascular invasion , need vascular reconstruction time surgery , treat LAT ablation temperature 90°C - Tumours locate head pancreas without radiologic macroscopic vascular invasion treat pancreaticoduodenectomy LAT 90°C - Tumours locate body tail pancreas treat resection LAT 90°C - Tumour drain lymph node remove Liver metastases - Tumours 3 cm treat LAT ( RFA MWA ) - Solitary tumour measure 3 - 5 cm treat resection - Superficial peripheral liver metastasis ( diameter 5 cm ) allow resect Peritoneal metastases - Peritonectomy , electrofulguration superficial ( &lt; 3mm depth ) metastases , organ resection allow - HIPC administer immediately CRS : cisplatin dose 100 mg/m2 dissolve 3 litre normal saline heat less 41° Celsius infuse abdominal cavity sustain hyperthermic intraperitoneal chemotherapy 60 minute . Surgical reconstruction ( anastomosis ) perform HIPC . TRANSLATIONAL RESEARCH 1 . Perioperative quantification peritoneal circulate tumour cell - Real-time qRT-PCR base detection quantification CEA EpCAM mRNA transcript - Circulating tumour cell peripheral blood sample study end surgical procedure ( CRS+HIPC ) - Peritoneal tumour cell evaluate lavage fluid start surgery ( manipulation ) end CRS+HIPC 2 . Perioperative systemic cytokine profile lymphocyte immunophenotyping - Plasma concentration cytokine determine use BDTM Cytometric Bead Array ( CBA ) : IL-1β , IL-2 , IL-6 , IL-8 , IL-10 , IL-12p70 , IL-13 , IFN-γ , VEGF - The relative proportion absolute number B-lymphocytes ( CD19+ ) , T-lymphocytes ( CD3+ ) , NK cell ( CD56+CD3- ) , effector T cell ( CD3+CD4+ CD3+CD8+ ) , HLA-DR+ T cell ( CD3+HLA-DR+ ) regulatory T cell ( CD3+CD4+25+127low ) quantify flow cytometry . - Time-points cytokine immunophenotyping analysis : surgery ( d-1 ) , end surgery ( d0 ) , day ( d1 ) day 7 follow CRS+HIPC 3 . Gene-expression primary metastatic pancreatic cancer - To good understand cancer biology search novel diagnostic therapeutic target , fresh tissue sample primary tumour metastasis store RNA-later RNA-extraction future analysis . Hereto , sample obtain biliary , gastric , pancreatic cancer tissue store . Based fact pancreatic cancer associate bad prognosis , base ongoing research disease , gene expression study current project focus pancreatic cancer . - In close collaboration department pathology , store snap-frozen tissue sample surgically resect human pancreatic cancer future research . Clinical , histopathological , survival data 200 patient registered database . Tissue sample ( primary metastasis ) current study analyse together available 96 primary tumour sample already control representative high quality RNA study . These sample obtain patient early advance localized pancreatic cancer various tumour stage . Gene-expression study perform use Affymetrix HG U133 Plus 2.0 array primary metastatic tissue sample . These experiment conduct close collaboration microarray facility VIB KUL .</detailed_description>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Primary recurrent disease Histological confirmation primary ( recurrent ) metastatic disease Systemic chemotherapy and/or biological allow and/or CRS+HIPC Radiotherapy allow CRS+HIPC Patients must fail prior intraperitoneal platinumtherapy Age 18 75 year Patient Karnofsky performance scale ( KPS ) &gt; 80 ( normal activity bit effort ) Age &lt; 18 &gt; 75 year Pregnancy Any malignancy biliary , gastric , pancreatic adenocarcinoma Any metastatic disease outside abdominal compartment , pulmonary bone metastasis Peritoneal carcinomatosis index ( PCI ) &gt; 20 start CRS Peritoneal residual tumour nodule large 2.5 mm CRS ( CCR2 ) Clinical relevant ascites More 3 liver metastasis Solitary liver metastasis large 5 cm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>cytoreductive surgery</keyword>
	<keyword>peritoneal chemotherapy</keyword>
	<keyword>cisplatin</keyword>
	<keyword>cancer</keyword>
	<keyword>gastric</keyword>
	<keyword>biliary</keyword>
	<keyword>pancreas</keyword>
	<keyword>peritoneal metastasis</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>peritoneal carcinomatosis upper gastrointestinal cancer</keyword>
</DOC>